BioSpace News Archive

EnACT study of MAT2203 in cryptococcal meningitis received unanimous D ata and Safety Monitoring Board (DSMB) recommendation to pro ceed into second patient cohort – ENHANCE-IT s tudy of MAT9001 against Vascepa ® fully enrolled with topline data anticipated Q1 2021 ; Phase 3 program on track to initiate H1 2021 – – Management to ho st conference call today, Friday , November 6 th , at 8 : 3 0 a .m. ET –

Interferon beta therapy has been a first-line treatment or disease-modifying therapy for multiple sclerosis.

The evolution trajectories in the hepatitis B vaccine market is influenced and shaped by the various country-wide trends in hepatitis B vaccination in the worldwide population.

Jubilant Pharma Ltd. and Aavis Pharmaceuticals Inc. announce the launch of Hydroxychloroquine Sulfate tablets, 200 mg, a therapeutic equivalent version of Plaquenil 200 mg in the U.S. market.

Funds support clinical development of potent antibodies for the immunotherapy of COVID-19 and for BK virus infection in kidney transplant patients

Independent test-institutes have confirmed that Prebona Disinfect is extremely effective against the coronavirus - SARS CoV-2, COVID-19.

Octapharma announces that the final results from the phase III ProDERM study will be presented at the American College of Rheumatology (ACR) Convergence 2020 virtual meeting.

Epizyme, a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, announced that the company has entered into an amended and restated agreement with funds managed by Pharmakon Advisors, LP, an affiliate of Royalty Pharma, to expand its loan facility and plans to draw down $150 million.

Reported Net Product Sales of $34.3 Million Non-GAAP Net Product Sales of $33.7 Million; Increased 21.4% over Pro-Forma Second Quarter 2020 Non-GAAP Net Product Sales Consistent with Pro-Forma Prior Year Quarter Despite COVID-19 Related Sales Disruptions and Effects of Sales Force Integration Provides Updated Outlook for Remainder of 2020

Hillrom announced financial results for its fiscal fourth quarter and full year ended September 30, 2020, and provided financial guidance for fiscal 2021.